Morepen Sustainability Profile
Morepen Laboratories Limited, commonly known as Morepen, is a prominent player in the pharmaceutical and healthcare industry, headquartered in India. Established in 1984, the company has made significant strides in the development and manufacturing of a diverse range of products, including diagnostic kits, active pharmaceutical ingredients (APIs), and over-the-counter medications. With a strong operational presence across India and various international markets, Morepen is recognised for its commitment to quality and innovation. The company’s core offerings, such as its advanced diagnostic solutions and high-quality APIs, set it apart in a competitive landscape. Morepen's dedication to research and development has earned it a notable position in the market, reflecting its ongoing pursuit of excellence in healthcare solutions.
DitchCarbon Score
How does Morepen's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Morepen's score of 13 is lower than 93% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Morepen's reported carbon emissions
In 2025, Morepen Laboratories Limited reported significant carbon emissions from its operations in India, totalling approximately 7,128,947 kg CO2e for Scope 1 and about 18,888,099 kg CO2e for Scope 2, resulting in a combined total of around 29,295,013 kg CO2e for both scopes. This data reflects the company's commitment to transparency in its environmental impact. For the previous year, 2024, Morepen's emissions were reported as approximately 31,403,010 kg CO2e for Scope 1 and about 16,412,460 kg CO2e for Scope 2, indicating a notable increase in emissions compared to 2025. The company has not disclosed any Scope 3 emissions data, which typically includes indirect emissions from the supply chain and product use. Despite the lack of specific reduction targets or initiatives, Morepen Laboratories Limited is actively engaged in monitoring its carbon footprint. The company has not inherited emissions data from any parent organisation, ensuring that its reported figures are solely reflective of its own operations. Overall, Morepen's emissions data highlights the need for ongoing efforts to address climate change and improve sustainability practices within the pharmaceutical industry in India.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2023 | |
|---|---|
| Scope 1 | 31,403.01 |
| Scope 2 | 16,412.46 |
| Scope 3 | - |
How Carbon Intensive is Morepen's Industry?
How Carbon Intensive is Morepen's Location?
Morepen's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Morepen has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
